Carcinoma in situ of bronchus and lung (controls excluding all cancers)

CD2_INSITU_BRONCHUSLUNG_EXALLC

No definition available.

Endpoint definition

FinnGen phenotype data

individuals

diagram downward connector

Apply sex-specific rule None

diagram downward connector
diagram bullet

Check conditions

not C3_BRONCHUS_LUNG

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Hospital Discharge: ICD-10 D02.2&
Hospital discharge: ICD-9 2312
Cause of death: ICD-10 D02.2&
Cause of death: ICD-9 2312
Cancer registry: Topography ICD-O-3 C34
Cancer registry: Morphology ICD-O-3 ANY
Cancer registry: Behaviour codes 2

3 out of 7 registries used, show all original rules.

-

diagram downward connector

Check minimum number of events None

-

diagram downward connector

Include endpoints None

-

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

28

diagram downward connector
CD2_INSITU_BRONCHUSLUNG_EXALLC

Control definitions

Control exclude C3_CANCER, C3_CANCER_WIDE

Extra metadata

Level in the ICD hierarchy 3
First used in FinnGen datafreeze DF9
Parent code in ICD-10 D02
Name in latin Carcinoma in situ mammae

Similar endpoints

Summary Statistics

Key figures

All Female Male
Number of individuals 28 9 19
Unadjusted prevalence (%) 0.01 0.00 0.01
Mean age at first event (years) 69.11 72.37 67.56

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 - - - -
15 years - - - -
5 years - - - -
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

Index endpoint: CD2_INSITU_BRONCHUSLUNG_EXALLC – Carcinoma in situ of bronchus and lung (controls excluding all cancers)
GWS hits:

Survival analyses between endpoints

Plot

before Carcinoma in situ of bronchus and lung (controls excluding all cancers)
after Carcinoma in situ of bronchus and lung (controls excluding all cancers)

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Carcinoma in situ of bronchus and lung (controls excluding all cancers)

Endpoint not on priority list, no data to show.